Abstract:Dysfunction of the intestinal mucosal immune system and dysbiosis of the intestinal microflora can induce inflammatory bowel disease. However, drug-mediated clinical treatment remains a challenge due to its poor therapeutic efficacy and severe side effects. Herein, a ROS scavenging and inflammation-directed nanomedicine is designed and fabricated by coupling polydopamine nanoparticles with mCRAMP, an antimicrobial peptide, while wrapping macrophage membrane in the outer layer. The designed nanomedicine reduced the secretion of pro-inflammatory cytokines and elevate the expression of anti-inflammatory cytokine in vivo and in vitro inflammation models, demonstrating its significant ability of improving inflammatory responses. Importantly, the macrophage membrane encapsulated nanoparticles exhibit the obviously enhanced targeting performance in local inflamed tissues. Furthermore, the 16S rRNA sequencing of fecal microorganisms showed that probiotics increased and pathogenic bacteria were inhibited after oral delivery the nanomedicine, indicating that the designed nano platform played a significant role in optimizing intestinal microbiome. Taken together, the designed nanomedicine are not only easy to prepare and exhibit high biocompatibility, but also show the inflammatory targeting property, anti-inflammatory function and positive regulation of intestinal flora, thus providing a new idea for the intervention and treatment of colitis. Statement of significance Inflammatory bowel disease (IBD), a chronic and intractable disease, may lead to colon cancer in severe cases without effective treatment. However, clinical drugs are largely ineffective owing to insufficient therapeutic efficacies and side effects. Herein, we constructed a biomimetic polydopamine nanoparticle for oral administration to treat the IBD by modulating mucosal immune homeostasis and optimizing intestinal microorganisms. In vitro and in vivo experiments showed that the designed nanomedicine not only exhibits the anti-inflammatory function and inflammatory targeting property but also positively regulate the gut microflora. Taken together, the designed nanomedicine combined immunoregulation and intestinal microecology modulation to significantly enhance the therapeutic effect on colitis in mice, thus providing a new approach for the clinical treatment of colitis.

Orally Administrated Nucleotide-Delivery Particles from Microfluidics for Inflammatory Bowel Disease Treatment

An Orally Administrated Nucleotide-Delivery Vehicle Targeting Colonic Macrophages for the Treatment of Inflammatory Bowel Disease

Oral Administration of Inflammatory Microenvironment-Responsive Carrier-Free Infliximab Nanocomplex for the Targeted Treatment of Inflammatory Bowel Disease

A Programmable Oral Nanomotor Microcapsule for the Treatment of Inflammatory Bowel Disease

Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases

An oral delivery vehicle based on konjac glucomannan acetate targeting the colon for inflammatory bowel disease therapy

Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease

Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Orally‐Delivered, Cytokine‐Engineered Extracellular Vesicles for Targeted Treatment of Inflammatory Bowel Disease

Dual-Sensitive Carbohydrate-Based Nanosystem for Targeted Drug Delivery to Potentiate the Therapeutic Efficacy of Ulcerative Colitis

Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease

ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease

Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy

Dual‐Targeted Nanoparticle‐In‐Microparticle System for Ulcerative Colitis Therapy

Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease

Designing a microbial fermentation-functionalized alginate microsphere for targeted release of 5-ASA using nano dietary fiber carrier for inflammatory bowel disease treatment

Shikonin delivery nano system based on calcium alginate for targeted therapy of inflammatory bowel disease by modulating macrophage polarization

Inflammation-targeted Delivery of Urolithin A Mitigates Chemical- and Immune Checkpoint Inhibitor-Induced Colitis

Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy

Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease